


Table of Contents

Supplementary Table A: Reasons for the end of follow-up (GLP-1 receptor agonists vs sulfonylureas cohort)	2
Supplementary Figure A: Forest Plot Depicting Secondary Analyses Comparing GLP-1 receptor agonists with Sulfonylureas.....	3
Supplementary Figure B. Restricted Cubic Spline of Cohort Entry Period and the Association Between GLP-1 receptor agonists and Severe COPD Exacerbations	4
Supplementary Figure C: Forest Plot Depicting Sensitivity Analyses Comparing GLP-1 receptor agonists with Sulfonylureas.....	5
Supplementary Table B: Reasons for the end of follow-up (DPP-4 inhibitors vs sulfonylureas cohort)	6
Supplementary Figure D: Forest Plot Depicting Secondary Analyses Comparing DPP-4 inhibitors with Sulfonylureas.....	7
Supplementary Figure E. Restricted Cubic Spline of Cohort Entry Period and the Association Between DPP-4 inhibitors and Severe COPD Exacerbations	8
Supplementary Figure F: Forest Plot Depicting Sensitivity Analyses Comparing DPP-4 inhibitors with Sulfonylureas.....	9
Supplementary Table C: Reasons for the end of follow-up (SGLT-2 inhibitors vs sulfonylureas cohort)	10
Supplementary Figure G: Forest Plot Depicting Secondary Analyses Comparing SGLT-2 inhibitors with Sulfonylureas.....	11
Supplementary Figure H. Restricted Cubic Spline of Cohort Entry Period and the Association Between SGLT-2 inhibitors and Severe COPD Exacerbations	12
Supplementary Figure I: Forest Plot Depicting Sensitivity Analyses Comparing SGLT-2 inhibitors with Sulfonylureas.....	13


Supplementary Table A: Reasons for the end of follow-up (GLP-1 receptor agonists vs sulfonylureas cohort)

Reasons	Sulfonylurea	GLP-1 receptor agonists
Outcome	1261 (8.8%)	64 (5.1%)
Death	1343 (9.4%)	31 (2.5%)
Administration	2272 (15.9%)	355 (28.4%)
Discontinuation/switching	9383 (65.8%)	802 (64.1%)


Supplementary Figure A: Forest Plot Depicting Secondary Analyses Comparing GLP-1 receptor agonists with Sulfonylureas



Supplementary Figure B. Restricted Cubic Spline of Cohort Entry Period and the Association Between GLP-1 receptor agonists and Severe COPD Exacerbations




Supplementary Figure C: Forest Plot Depicting Sensitivity Analyses Comparing GLP-1 receptor agonists with Sulfonylureas




Supplementary Table B: Reasons for the end of follow-up (DPP-4 inhibitors vs sulfonylureas cohort)

Reasons	Sulfonylurea	DPP-4 inhibitors
Outcome	1827 (10.0%)	611 (7.0%)
Death	2233 (12.3%)	665 (7.6%)
Administration	2731 (15.0%)	2850 (32.6%)
Discontinuation/switching	11,413 (62.7%)	4605 (52.7%)


Supplementary Figure D: Forest Plot Depicting Secondary Analyses Comparing DPP-4 inhibitors with Sulfonylureas



Supplementary Figure E. Restricted Cubic Spline of Cohort Entry Period and the Association Between DPP-4 inhibitors and Severe COPD Exacerbations




Supplementary Figure F: Forest Plot Depicting Sensitivity Analyses Comparing DPP-4 inhibitors with Sulfonylureas




Supplementary Table C: Reasons for the end of follow-up (SGLT-2 inhibitors vs sulfonylureas cohort)

Reasons	Sulfonylurea	SGLT-2 inhibitors
Outcome	1006 (9.3%)	92 (3.1%)
Death	1144 (10.6%)	62 (2.1%)
Administration	2731 (25.2%)	1249 (42.3%)
Discontinuation/switching	5960 (55.0%)	1553 (52.5%)

Supplementary Figure G: Forest Plot Depicting Secondary Analyses Comparing SGLT-2 inhibitors with Sulfonylureas



Supplementary Figure H. Restricted Cubic Spline of Cohort Entry Period and the Association Between SGLT-2 inhibitors and Severe COPD Exacerbations



Supplementary Figure I: Forest Plot Depicting Sensitivity Analyses Comparing SGLT-2 inhibitors with Sulfonylureas

